Literature DB >> 24583248

A switch in the source of ATP production and a loss in capacity to perform glycolysis are hallmarks of hepatocyte failure in advance liver disease.

Taichiro Nishikawa1, Nadège Bellance2, Aaron Damm2, Han Bing3, Zhen Zhu4, Kan Handa5, Mladen I Yovchev5, Vasudha Sehgal6, Tyler J Moss6, Michael Oertel5, Prahlad T Ram6, Iraklis I Pipinos4, Alejandro Soto-Gutierrez7, Ira J Fox8, Deepak Nagrath9.   

Abstract

BACKGROUND & AIMS: The cause of hepatic failure in the terminal stages of chronic injury is unknown. Cellular metabolic adaptations in response to the microenvironment have been implicated in cellular breakdown.
METHODS: To address the role of energy metabolism in this process we studied mitochondrial number, respiration, and functional reserve, as well as cellular adenosine-5'-triphosphate (ATP) production, glycolytic flux, and expression of glycolysis related genes in isolated hepatocytes from early and terminal stages of cirrhosis using a model that produces hepatic failure from irreversible cirrhosis in rats. To study the clinical relevance of energy metabolism in terminal stages of chronic liver failure, we analyzed glycolysis and energy metabolism related gene expression in liver tissue from patients at different stages of chronic liver failure according to Child-Pugh classification. Additionally, to determine whether the expression of these genes in early-stage cirrhosis (Child-Pugh Class A) is related to patient outcome, we performed network analysis of publicly available microarray data obtained from biopsies of 216 patients with hepatitis C-related Child-Pugh A cirrhosis who were prospectively followed up for a median of 10years.
RESULTS: In the early phase of cirrhosis, mitochondrial function and ATP generation are maintained by increasing energy production from glycolytic flux as production from oxidative phosphorylation falls. At the terminal stage of hepatic injury, mitochondria respiration and ATP production are significantly compromised, as the hepatocytes are unable to sustain the increased demand for high levels of ATP generation from glycolysis. This impairment corresponds to a decrease in glucose-6-phosphatase catalytic subunit and phosphoglucomutase 1. Similar decreased gene expression was observed in liver tissue from patients at different stages of chronic liver injury. Further, unbiased network analysis of microarray data revealed that expression of these genes was down regulated in the group of patients with poor outcome.
CONCLUSIONS: An adaptive metabolic shift, from generating energy predominantly from oxidative phosphorylation to glycolysis, allows maintenance of energy homeostasis during early stages of liver injury, but leads to hepatocyte dysfunction during terminal stages of chronic liver disease because hepatocytes are unable to sustain high levels of energy production from glycolysis.
Copyright © 2014 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acute-in-chronic liver failure; Adenosine-5′-triphosphate; Decompensated liver cirrhosis; Glycolysis; Hepatocytes; Mitochondria

Mesh:

Substances:

Year:  2014        PMID: 24583248      PMCID: PMC4028384          DOI: 10.1016/j.jhep.2014.02.014

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  41 in total

Review 1.  Adaptation of mitochondrial metabolism in liver cirrhosis. Different strategies to maintain a vital function.

Authors:  S Krähenbühl; J Reichen
Journal:  Scand J Gastroenterol Suppl       Date:  1992

2.  Reduced activity of the electron transport chain in liver mitochondria isolated from rats with secondary biliary cirrhosis.

Authors:  S Krähenbühl; J Stucki; J Reichen
Journal:  Hepatology       Date:  1992-06       Impact factor: 17.425

Review 3.  Branched-chain amino acids as pharmacological nutrients in chronic liver disease.

Authors:  Takumi Kawaguchi; Namiki Izumi; Michael R Charlton; Michio Sata
Journal:  Hepatology       Date:  2011-06-23       Impact factor: 17.425

4.  Serum metabolomics reveals the deregulation of fatty acids metabolism in hepatocellular carcinoma and chronic liver diseases.

Authors:  Lina Zhou; Quancai Wang; Peiyuan Yin; Wenbin Xing; Zeming Wu; Shili Chen; Xin Lu; Yong Zhang; Xiaohui Lin; Guowang Xu
Journal:  Anal Bioanal Chem       Date:  2012-02-14       Impact factor: 4.142

5.  The microenvironment in hepatocyte regeneration and function in rats with advanced cirrhosis.

Authors:  Liping Liu; Govardhana Rao Yannam; Taichiro Nishikawa; Toshiyuki Yamamoto; Hesham Basma; Ryotaro Ito; Masaki Nagaya; Joyeeta Dutta-Moscato; Donna B Stolz; Fenghai Duan; Klaus H Kaestner; Yoram Vodovotz; Alejandro Soto-Gutierrez; Ira J Fox
Journal:  Hepatology       Date:  2012-04-04       Impact factor: 17.425

6.  Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis.

Authors:  Vasiliki Arvaniti; Gennaro D'Amico; Giuseppe Fede; Pinelopi Manousou; Emmanuel Tsochatzis; Maria Pleguezuelo; Andrew Kenneth Burroughs
Journal:  Gastroenterology       Date:  2010-06-14       Impact factor: 22.682

7.  Serum metabolomics reveals γ-glutamyl dipeptides as biomarkers for discrimination among different forms of liver disease.

Authors:  Tomoyoshi Soga; Masahiro Sugimoto; Masashi Honma; Masayo Mori; Kaori Igarashi; Kasumi Kashikura; Satsuki Ikeda; Akiyoshi Hirayama; Takehito Yamamoto; Haruhiko Yoshida; Motoyuki Otsuka; Shoji Tsuji; Yutaka Yatomi; Tadayuki Sakuragawa; Hisayoshi Watanabe; Kouei Nihei; Takafumi Saito; Sumio Kawata; Hiroshi Suzuki; Masaru Tomita; Makoto Suematsu
Journal:  J Hepatol       Date:  2011-02-18       Impact factor: 25.083

Review 8.  Acute-on chronic liver failure.

Authors:  Rajiv Jalan; Pere Gines; Jody C Olson; Rajeshwar P Mookerjee; Richard Moreau; Guadalupe Garcia-Tsao; Vicente Arroyo; Patrick S Kamath
Journal:  J Hepatol       Date:  2012-06-28       Impact factor: 25.083

9.  Oncosecretomics coupled to bioenergetics identifies α-amino adipic acid, isoleucine and GABA as potential biomarkers of cancer: Differential expression of c-Myc, Oct1 and KLF4 coordinates metabolic changes.

Authors:  Nadège Bellance; Lisa Pabst; Genevara Allen; Rodrigue Rossignol; Deepak Nagrath
Journal:  Biochim Biophys Acta       Date:  2012-07-25

10.  The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4.

Authors:  Rommel G Tirona; Wooin Lee; Brenda F Leake; Lu-Bin Lan; Cynthia Brimer Cline; Vishal Lamba; Fereshteh Parviz; Stephen A Duncan; Yusuke Inoue; Frank J Gonzalez; Erin G Schuetz; Richard B Kim
Journal:  Nat Med       Date:  2003-01-06       Impact factor: 53.440

View more
  46 in total

Review 1.  Liver-Regenerative Transplantation: Regrow and Reset.

Authors:  A Collin de l'Hortet; K Takeishi; J Guzman-Lepe; K Handa; K Matsubara; K Fukumitsu; K Dorko; S C Presnell; H Yagi; A Soto-Gutierrez
Journal:  Am J Transplant       Date:  2016-02-18       Impact factor: 8.086

2.  Salvianolate Reduces Glucose Metabolism Disorders in Dimethylnitrosamine-Induced Cirrhotic Rats.

Authors:  Li-Rui Tang; Yan-Yan Tao; Cheng-Hai Liu; Hai-Nan Wang
Journal:  Chin J Integr Med       Date:  2017-12-05       Impact factor: 1.978

3.  Reply to: "Is the pathway of energy metabolism modified in advanced cirrhosis?".

Authors:  Deepak Nagrath; Alejandro Soto-Gutierrez
Journal:  J Hepatol       Date:  2014-05-02       Impact factor: 25.083

4.  Effects of beta-hydroxy-beta-methylbutyrate supplementation on skeletal muscle in healthy and cirrhotic rats.

Authors:  Milan Holeček; Melita Vodeničarovová
Journal:  Int J Exp Pathol       Date:  2019-07-18       Impact factor: 1.925

Review 5.  Regulation of hepatocyte identity and quiescence.

Authors:  Carmen Berasain; Matías A Avila
Journal:  Cell Mol Life Sci       Date:  2015-06-19       Impact factor: 9.261

6.  Cross-Organ Transcriptomic Comparison Reveals Universal Factors During Maturation.

Authors:  Sandeep Kambhampati; Sean Murphy; Hideki Uosaki; Chulan Kwon
Journal:  J Comput Biol       Date:  2022-07-08       Impact factor: 1.549

Review 7.  Enzymatic and nonenzymatic protein acetylations control glycolysis process in liver diseases.

Authors:  Juan Li; Tongxin Wang; Jun Xia; Weilei Yao; Feiruo Huang
Journal:  FASEB J       Date:  2019-08-01       Impact factor: 5.191

8.  Deregulation of energy metabolism promotes antifibrotic effects in human hepatic stellate cells and prevents liver fibrosis in a mouse model.

Authors:  Swathi Karthikeyan; James J Potter; Jean-Francois Geschwind; Surojit Sur; James P Hamilton; Bert Vogelstein; Kenneth W Kinzler; Esteban Mezey; Shanmugasundaram Ganapathy-Kanniappan
Journal:  Biochem Biophys Res Commun       Date:  2015-10-23       Impact factor: 3.575

Review 9.  The Inside-Out of End-Stage Liver Disease: Hepatocytes are the Keystone.

Authors:  Nils Haep; Rodrigo M Florentino; James E Squires; Aaron Bell; Alejandro Soto-Gutierrez
Journal:  Semin Liver Dis       Date:  2021-05-15       Impact factor: 6.115

10.  BAM15, a Mitochondrial Uncoupling Agent, Attenuates Inflammation in the LPS Injection Mouse Model: An Adjunctive Anti-Inflammation on Macrophages and Hepatocytes.

Authors:  Cong Phi Dang; Jiraphorn Issara-Amphorn; Awirut Charoensappakit; Kanyarat Udompornpitak; Thansita Bhunyakarnjanarat; Wilasinee Saisorn; Kritsanawan Sae-Khow; Asada Leelahavanichkul
Journal:  J Innate Immun       Date:  2021-06-01       Impact factor: 7.349

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.